Not Disclosed

Drug Name: Not Disclosed
Company: Anelixis Therapeutics
Location: US – Massachusetts
Drug Type: Small Molecule
Conditions: ALS
Mechanism Type: Proteostasis, Misfolded SOD1
Mechanism: The company is aiming to identify small molecules that bind the misfolded SOD1 dimer and stabilize it, thereby preventing aggregation and seeding of protein misfolding in wild-type SOD1. Efforts are focused on medicinal chemistry followed by in vivo and in vitro optimization to identify compounds optimized for human testing.
U.S. Status for ALS: Preclinical

[1] SOD1 Program. Anelixis Therapeutics, 2016. Accessed 28 Dec 2015 from

Last updated December 28th, 2015

Share this: